Summit X LLC’s Biogen BIIB Stock Holding History

Summit X LLC’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-51	Closed	-$567	–	266
2020 Q3	$567	Buy	+51	New	+$14.2K	0.01%	294

Other funds holding BIIB

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Summit X LLC's BIIB Position: Q4 2020 in Review

Summit X LLC sold out of Biogen (BIIB) in Q4 2020, closing a stake of 51 shares — an estimated $567 sold.

Summit X LLC first reported a position in BIIB in Q3 2020 and held it in 1 quarter. The position peaked at $567 in Q3 2020. 1,060 funds tracked by Wall St. Rank hold BIIB as of Q4 2020.

Summit X LLC reported no remaining Biogen position as of Q4 2020 after selling out during the quarter.
Summit X LLC sold 51 Biogen shares in Q4 2020, an estimated $567.
Summit X LLC first reported a position in Biogen in Q3 2020 and held it in 1 quarter.
Summit X LLC's Biogen position peaked at $567 in Q3 2020.
1,060 funds tracked by Wall St. Rank held Biogen as of Q4 2020.

Based on Summit X LLC's 13F filing for Q4 2020, filed 29 Jan 2021.